Scroll

doconexent 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4289	6217-54-5

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: docosahexaenoic acid doconexent cervonic acid efalex	a mixture of fish oil and primrose oil; used as a high-docosahexaenoic acid fatty acid supplement Molecular weight: 328.50 Formula: C22H32O2 CLOGP: 7.48 LIPINSKI: 1 HAC: 2 HDO: 1 TPSA: 37.30 ALOGS: -6.25 ROTB: 14

Molecule

Description

Molfile Inchi Smiles

Synonyms:

docosahexaenoic acid
doconexent
cervonic acid
efalex

a mixture of fish oil and primrose oil; used as a high-docosahexaenoic acid fatty acid supplement

Molecular weight: 328.50
Formula: C22H32O2
CLOGP: 7.48
LIPINSKI: 1
HAC: 2
HDO: 1
TPSA: 37.30
ALOGS: -6.25
ROTB: 14

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
None	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Pneumonia aspiration	158.67	40.06	66	4139	34474	63450343
Coma	119.54	40.06	66	4139	64298	63420519
Gastrooesophageal reflux disease	95.44	40.06	66	4139	95573	63389244
Muscle spasticity	84.62	40.06	37	4168	21757	63463060
Rheumatic disorder	81.29	40.06	22	4183	3050	63481767
Respiratory disorder	72.27	40.06	40	4165	39042	63445775
Blood immunoglobulin M increased	69.76	40.06	16	4189	1127	63483690
Body temperature increased	68.59	40.06	38	4167	37154	63447663
Incorrect route of product administration	67.51	40.06	34	4171	27418	63457399
Blood immunoglobulin A decreased	67.51	40.06	16	4189	1301	63483516
Ear pain	66.87	40.06	37	4168	36081	63448736
Somnolence	66.66	40.06	70	4135	178615	63306202
Blood immunoglobulin G increased	57.80	40.06	16	4189	2411	63482406
Hepatic enzyme abnormal	57.58	40.06	20	4185	6372	63478445
Colitis microscopic	57.25	40.06	22	4183	9317	63475500
Night sweats	56.56	40.06	37	4168	48777	63436040
Cataract operation	56.46	40.06	19	4186	5503	63479314
Skin reaction	53.72	40.06	24	4181	14825	63469992
Hernia	50.91	40.06	22	4183	12552	63472265
Psoriatic arthropathy	49.45	40.06	44	4161	91476	63393341
Multiple allergies	48.95	40.06	22	4183	13780	63471037
Sinusitis	47.06	40.06	66	4139	226587	63258230
Insomnia	45.15	40.06	63	4142	215189	63269628
Glaucoma	42.36	40.06	22	4183	18883	63465934

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Child abuse	89.40	42.51	16	4094	413	79739865
Rheumatic disorder	86.16	42.51	22	4088	3136	79737142
Pneumonia aspiration	79.42	42.51	47	4063	66920	79673358
Epidural lipomatosis	78.18	42.51	17	4093	1211	79739067
Muscle spasticity	73.52	42.51	31	4079	21444	79718834
Blood immunoglobulin M increased	70.92	42.51	16	4094	1350	79738928
Blood immunoglobulin A decreased	69.94	42.51	16	4094	1437	79738841
Incorrect route of product administration	67.83	42.51	34	4076	34895	79705383
Psoriatic arthropathy	65.50	42.51	44	4066	77955	79662323
Cataract operation	62.33	42.51	19	4091	5166	79735112
Coma	61.99	42.51	47	4063	100602	79639676
Ear pain	60.91	42.51	31	4079	32838	79707440
Gastrooesophageal reflux disease	60.52	42.51	47	4063	104199	79636079
Multiple allergies	60.19	42.51	22	4088	10438	79729840
Colitis microscopic	59.57	42.51	22	4088	10746	79729532
Hepatic enzyme abnormal	58.56	42.51	20	4090	7790	79732488
Blood immunoglobulin G increased	58.47	42.51	16	4094	2973	79737305
Skin reaction	57.69	42.51	24	4086	16044	79724234
Juvenile idiopathic arthritis	55.32	42.51	17	4093	4746	79735532
Body temperature increased	54.80	42.51	32	4078	44388	79695890
Sinusitis	52.12	42.51	57	4053	195444	79544834
Respiratory disorder	51.89	42.51	31	4079	44825	79695453
Hernia	49.77	42.51	22	4088	17037	79723241
Contraindicated product administered	49.22	42.51	50	4060	157488	79582790
Night sweats	47.62	42.51	31	4079	52064	79688214
Glaucoma	46.67	42.51	22	4088	19739	79720539
Victim of child abuse	43.22	42.51	10	4100	943	79739335
Eye disorder	43.13	42.51	22	4088	23390	79716888
Joint swelling	43.09	42.51	63	4047	288583	79451695
Multiple fractures	42.93	42.51	16	4094	8010	79732268

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
CHEBI has role	CHEBI:35610	antineoplastic agents
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:83146	Daphnia tenebrosa metabolites
CHEBI has role	CHEBI:84735	algal metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID
Pregnancy, function	indication	289908002
Breastfeeding (mother)	indication	413712001
Prevention of Fetal Neural Tube Defects during Pregnancy	off-label use

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.37	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source
Aromatase	Enzyme	P11511	CP19A_HUMAN		IC50	4.48	CHEMBL
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN		Ki	5.20	CHEMBL
Free fatty acid receptor 1	GPCR	O14842	FFAR1_HUMAN	AGONIST	EC50	6	IUPHAR
Oxoeicosanoid receptor 1	GPCR	Q8TDS5	OXER1_HUMAN		IC50	5.70	CHEMBL
Prostaglandin G/H synthase 2	Enzyme		PGH2_SHEEP		IC50	5.01	CHEMBL
Prostaglandin G/H synthase 1	Enzyme		PGH1_BOVIN		IC50	4.82	CHEMBL
Transient receptor potential cation channel subfamily A member 1	Ion channel		TRPA1_RAT	ACTIVATOR	EC50	4.40	IUPHAR

External reference:

ID	Source
4020132	VUID
N0000148111	NUI
4020132	VANDF
C2348308	UMLSCUI
CHEBI:28125	CHEBI
F22	PDB_CHEM_ID
HXA	PDB_CHEM_ID
CHEMBL367149	ChEMBL_ID
DB03756	DRUGBANK_ID
C532150	MESH_SUPPLEMENTAL_RECORD_UI
1051	IUPHAR_LIGAND_ID
6428	INN_ID
ZAD9OKH9JC	UNII
445580	PUBCHEM_CID
1006469	RXNORM
002051	NDDF
226368001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
CitraNatal Harmony 3.0	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0796	CAPSULE, GELATIN COATED	260 mg	ORAL	unapproved drug other	10 sections
CitraNatal Harmony 3.0	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0796	CAPSULE, GELATIN COATED	260 mg	ORAL	unapproved drug other	10 sections
CitraNatal Harmony	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0798	CAPSULE, GELATIN COATED	260 mg	ORAL	UNAPPROVED DRUG OTHER	11 sections
CitraNatal Harmony	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0799	CAPSULE, GELATIN COATED	250 mg	ORAL	Unapproved drug other	11 sections
CitraNatal Harmony	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0812	CAPSULE, GELATIN COATED	250 mg	ORAL	Unapproved drug other	11 sections
CitraNatal Medley	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0896	CAPSULE, GELATIN COATED	200 mg	ORAL	unapproved drug other	10 sections
CitraNatal Medley	HUMAN PRESCRIPTION DRUG LABEL	8	0178-0896	CAPSULE, GELATIN COATED	200 mg	ORAL	unapproved drug other	10 sections
Vitafol Ultra	HUMAN PRESCRIPTION DRUG LABEL	17	0642-0093	CAPSULE, LIQUID FILLED	200 mg	ORAL	UNAPPROVED DRUG OTHER	13 sections
Vitafol Ultra	HUMAN PRESCRIPTION DRUG LABEL	17	0642-0093	CAPSULE, LIQUID FILLED	200 mg	ORAL	UNAPPROVED DRUG OTHER	13 sections
Vitafol Fe Plus	HUMAN PRESCRIPTION DRUG LABEL	17	0642-7473	CAPSULE, LIQUID FILLED	200 mg	ORAL	UNAPPROVED DRUG OTHER	14 sections
Vitafol Fe Plus	HUMAN PRESCRIPTION DRUG LABEL	17	0642-7473	CAPSULE, LIQUID FILLED	200 mg	ORAL	UNAPPROVED DRUG OTHER	14 sections
TriStart DHA	HUMAN PRESCRIPTION DRUG LABEL	15	15370-250	CAPSULE, LIQUID FILLED	200 mg	ORAL	UNAPPROVED DRUG OTHER	12 sections
PNV-DHA	HUMAN PRESCRIPTION DRUG LABEL	10	42192-321	CAPSULE, GELATIN COATED	300 mg	ORAL	unapproved drug other	11 sections
PNV-DHA	HUMAN PRESCRIPTION DRUG LABEL	8	42192-323	CAPSULE, GELATIN COATED	300 mg	ORAL	unapproved drug other	11 sections
PNV-Omega	HUMAN PRESCRIPTION DRUG LABEL	13	42192-332	CAPSULE, GELATIN COATED	300 mg	ORAL	unapproved drug other	12 sections
Prenaissance	HUMAN PRESCRIPTION DRUG LABEL	9	42192-341	CAPSULE, LIQUID FILLED	325 mg	ORAL	UNAPPROVED DRUG OTHER	10 sections
Prenaissance Plus	HUMAN PRESCRIPTION DRUG LABEL	8	42192-343	CAPSULE, LIQUID FILLED	250 mg	ORAL	UNAPPROVED DRUG OTHER	10 sections
Animi-3 with Vitamin D	HUMAN PRESCRIPTION DRUG LABEL	8	66213-542	CAPSULE	250 mg	ORAL	unapproved drug other	14 sections
Animi-3	HUMAN PRESCRIPTION DRUG LABEL	8	66213-543	CAPSULE	250 mg	ORAL	unapproved drug other	14 sections
TRICARE PRENATAL DHA ONE	HUMAN PRESCRIPTION DRUG LABEL	17	67112-401	CAPSULE, GELATIN COATED	215 mg	ORAL	unapproved drug other	12 sections
PRENATE Restore	HUMAN PRESCRIPTION DRUG LABEL	12	75854-308	CAPSULE, GELATIN COATED	400 mg	ORAL	unapproved drug other	13 sections
PRENATE Enhance	HUMAN PRESCRIPTION DRUG LABEL	12	75854-309	CAPSULE, GELATIN COATED	400 mg	ORAL	unapproved drug other	13 sections
PRENATE DHA	HUMAN PRESCRIPTION DRUG LABEL	10	75854-312	CAPSULE, GELATIN COATED	300 mg	ORAL	unapproved drug other	13 sections
Prenate Essential	HUMAN PRESCRIPTION DRUG LABEL	14	75854-313	CAPSULE, GELATIN COATED	300 mg	ORAL	unapproved drug other	13 sections
Prenate Mini	HUMAN PRESCRIPTION DRUG LABEL	15	75854-315	CAPSULE, GELATIN COATED	350 mg	ORAL	unapproved drug other	12 sections